PHS
CAPR icon

PFM Health Sciences’s Capricor Therapeutics CAPR Stock Holding History

PFM Health Sciences’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Sell
122,221
-1,610
-1% -$48.8K 0.25% 81
2026
Q1 		$3.76M Buy
+123,831
New +$3.3M 0.34% 70
2025
Q2 		– Sell
-140,681
Closed -$1.34M – 62
2025
Q1 		$1.34M Buy
140,681
+86,324
+159% +$1.2M 0.1% 55
2024
Q4 		$750K Sell
54,357
-98,422
-64% -$1.72M 0.05% 79
2024
Q3 		$2.32M Buy
+152,779
New +$756K 0.13% 64

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PFM Health Sciences's CAPR Position: Q2 2026 in Review

PFM Health Sciences reduced its Capricor Therapeutics (CAPR) stake by 1.3% in Q2 2026, selling an estimated $48.8K and leaving 122,221 shares worth $2.94M. The position accounts for 0.25% of the portfolio, ranked #81.

PFM Health Sciences first reported a position in CAPR in Q3 2024 and has held it in 5 quarters since. The position peaked at $3.76M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • PFM Health Sciences held 122,221 shares of Capricor Therapeutics worth $2.94M as of Q2 2026.
  • PFM Health Sciences sold 1,610 Capricor Therapeutics shares in Q2 2026, an estimated $48.8K.
  • Capricor Therapeutics made up 0.25% of PFM Health Sciences's portfolio in Q2 2026, its #81 holding.
  • PFM Health Sciences first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • PFM Health Sciences's Capricor Therapeutics position peaked at $3.76M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.